Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

A new childhood obesity guideline in Canada recommends weight-loss drugs for kids as young as 12, despite limited long-term ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

A cross-sectional analysis of firearm injury-related emergency department (ED) visits found that between 2018 and 2023, there was approximately one firearm injury ED visit every 30 minutes in the 10 ...

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

A study led by two undergraduate students at the University of Galway found that GLP-1 receptor agonists, a type of diabetes ...